Pharmaceutical company Mayne Pharma Group Limited (ASX:MYX) said on Thursday that it has launched its butalbital acetaminophen and caffeine (BAC) capsule in 50mg/300mg/40mg in the United States for the treatment of tension headache (migraine).
It comes after the company received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application for BAC.
US sales of BAC capsule 50mg/300mg/40mg were approximately USD40m for the 12 months ending 31 March 2020, according to IQVIA.
Mayne Pharma markets more than 60 generic and specialty branded pharmaceuticals in the US.
FDA approves antibiotic Recarbrio to treat HABP/VABP in adult patients
GenScript files for FDA's EUA for rapid SARS-CoV-2 neutralization antibody detection kit
Clarity Pharmaceuticals receives FDA Rare Pediatric Disease Designation for 67Cu-SARTATE